Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.

ABSTRACT:

Background and purpose

Bruton's tyrosine kinase (Btk) is a non-receptor tyrosine kinase involved in the activation of signalling pathways responsible for cell maturation and viability. Btk has previously been reported to be overexpressed in colon cancers. This kind of cancer is often accompanied by anaemia, which is treated with an erythropoietin supplement. The goal of the present study was to assess the effects of combination therapy with erythropoietin β (Epo) and LFM-A13 (Btk inhibitor) on colon cancer in in vitro and in vivo models.

Experimental approach

DLD-1 and HT-29 human colon adenocarcinoma cells were cultured with Epo and LFM-A13. Cell number and viability, and mRNA and protein levels of Epo receptors, Btk and Akt were assessed. Nude mice were inoculated with ade

SUBMITTER: Tankiewicz-Kwedlo A 

PROVIDER: S-EPMC5811618 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature